Immunotherapy in Oncology
We recommend
Expression of PD-L1 in Patients with Advanced Non-Small Cell Lung Cancer
An international team of authors published a systematic review addressing the relationship between the programmed cell death receptor ligand (PD-L1) and important clinical characteristics of patients with non-small cell lung cancer (NSCLC), the significance of PD-L1 expression for NSCLC prognosis, and the potential use of this biomarker to predict the response of patients with advanced/metastatic NSCLC to therapies targeting the PD-1/PD-L1 pathway.
Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer
Antibodies against the programmed cell death protein 1 (PD-1) improve the survival of patients with…
Case Study of a Patient with NSCLC − with Voting
Presented by: MUDr. Leona Koubková,
Pneumology Clinic, 2nd Faculty of Medicine, Charles University...
Articles on this topic
Immunotherapy of Cancer Diseases
Immunotherapeutic strategies have been successfully utilized recently in the treatment of various...
Subscribe
Most read on this topic
Journal on this topic
Related topic
Interesting links
Most read on this topic
- Immunotherapy of Cancer Diseases
- Expression of PD-L1 in Patients with Advanced Non-Small Cell Lung Cancer
- Case Study of a Patient with NSCLC − with Voting
- Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer
Journal on this topic
Related topic
Interesting links